Categories
Uncategorized

As Holdout Missouri Joins Nation in Monitoring Opioid Prescriptions, Experts Worry

Kathi Arbini said she felt elated when Missouri finally caught up to the other 49 states and approved a statewide prescription drug monitoring program this June in an attempt to curb opioid addiction. The hairstylist turned activist estimated she made 75 two-hour trips in the past decade from her home in Fenton, a St. Louis […]

Categories
Uncategorized

Journalists Dig in on Delta Variant Risks and Opioid Overdose Deaths

KHN Midwest correspondent Lauren Weber discussed outbreaks caused by the covid-19 delta variant in Missouri and elsewhere on Newsy on Thursday. KHN correspondent Aneri Pattani discussed opioids and the rise in overdose deaths on Newsy’s “Morning Rush” on July 16. Related Topics Contact Us Submit a Story Tip Source

Categories
Uncategorized

Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign

Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? Those are two of the six questions in a quiz on a website co-sponsored by the makers of Aduhelm, a controversial new Alzheimer’s drug. But even when all responses to the frequency of those experiences are […]

Categories
Uncategorized

Journalists’ Topics Range From Rural Pharmacy Deserts to Opioid Overdoses

KHN senior Colorado correspondent Markian Hawryluk discussed how a rural Colorado town is crowdsourcing ways to get prescription medicines delivered on KUNC’s “Colorado Edition” on Monday. KHN Editor-in-Chief Elisabeth Rosenthal discussed how medical education changed during the pandemic on NPR’s “Here and Now” on Tuesday. KHN freelancer Amy Worden chatted about high vaccine hesitancy among […]

Categories
Uncategorized

KHN’s ‘What the Health?’: Here Comes Reconciliation

Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The expansion of health benefits is a major piece of the tentative budget deal reached this week by Democrats in Congress. They plan to press ahead — […]

Categories
Uncategorized

Dying Patients With Rare Diseases Struggle to Get Experimental Therapies

At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington’s disease. “There’s lots of things that she used to be able to do just fine,” said her mom, Londen Tabor, who lives with her […]

Categories
Uncategorized

KHN’s ‘What the Health?’: Becerra Urges Congress to Expand Medicare, Address Rx Prices

Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The Biden administration stands ready to work with Congress to address drug prices and expand Medicare, Health and Human Services Secretary Xavier Becerra said in a wide-ranging […]

Categories
Uncategorized

Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works

The Food and Drug Administration’s approval in June of a drug purporting to slow the progression of Alzheimer’s disease was widely celebrated, but it also touched off alarms. There were worries in the scientific community about the drug’s mixed results in studies — the FDA’s own expert advisory panel was nearly unanimous in opposing its […]

Categories
Uncategorized

Doctores sopesan pros y contras de recetar la nueva droga para el Alzheimer

Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”. Los médicos no tienen una respuesta definitiva. “En cada persona, será absolutamente imposible de predecir”, dijo el doctor Allan Levey, director del Centro de Investigación […]

Categories
Uncategorized

Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say

The largest drug companies are far more interested in enriching themselves and investors than in developing new drugs, according to a House committee report released Thursday that argues the industry can afford to charge Medicare less for prescriptions. The report by the House Oversight and Reform Committee says that contrary to pharmaceutical industry arguments that […]